Duravyu Misses Wet AMD Noninferiority Target
EyePoint's phase 3 LUGANO trial did not meet its primary visual acuity endpoint against Regeneron's Eylea in wet macular degeneration.
Updated on Nov. 9, 2026 in Biotech

The phase 3 LUGANO trial of Duravyu, formerly EYP-1901, did not meet its primary endpoint of noninferiority in visual acuity compared with Eylea 2 mg in patients with wet age-related macular degeneration. Results were presented at the American Academy of Ophthalmology meeting.
Why it matters
The result is a setback for EyePoint's sustained-release approach, which would allow patients to receive treatment every six months rather than every eight weeks. A post hoc analysis excluding nine patients with vision loss unrelated to macular drying showed Duravyu reached noninferiority, but that exclusion was not part of the prespecified analysis.
The LUGANO trial randomized wet AMD patients to Duravyu every six months or Eylea every eight weeks, and nine Duravyu patients lost vision unrelated to macular drying. Excluding those nine in a post hoc analysis reached noninferiority, but the cause of their vision loss has not been explained.
The players
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is the developer of Duravyu, formerly known as EYP-1901, a sustained-release treatment for retinal disease.
Regeneron
Regeneron manufactures Eylea, the aflibercept 2 mg anti-VEGF therapy used as the comparator in the LUGANO trial.
The details
Patients with wet AMD in the LUGANO trial received either Duravyu, a vorolanib intravitreal insert, or Eylea 2 mg, manufactured by Regeneron. Results from the identical LUCIA trial are expected in the coming weeks and may show whether Duravyu can meet noninferiority.
Timeline
November 2026: LUGANO results presented at the American Academy of Ophthalmology meeting in New Orleans.
Next couple of weeks: Expected LUCIA trial results.
Health Landscape
The LUCIA trial, which uses an identical design to LUGANO, will determine whether Duravyu's noninferiority to Eylea holds across a second trial population. Its result will shape whether sustained-release anti-VEGF treatments can replace frequent intravitreal injections in wet AMD care.
Patients with wet AMD who rely on frequent injections could eventually benefit from a six-month dosing schedule if Duravyu succeeds. For now, the LUGANO result means current treatment schedules with Eylea and similar drugs remain the established option.
The takeaway
A single trial's post hoc result does not settle a drug's efficacy, so the upcoming LUCIA data will be the more informative signal for Duravyu's future. Patients and clinicians should watch that readout before assuming a longer dosing interval is viable.
What happens next
Results from the LUCIA trial are expected in the next couple of weeks and will indicate whether Duravyu can meet the noninferiority endpoint against Eylea 2 mg every eight weeks.
Further reading
Explore more Biotech developments shaping drug development in the United States.






